Eurofins Scientific Se · EURONEXT:ERF
Eurofins Scientific — Q1 2020 Earnings Presentation
22 slides from Eurofins Scientific's earnings presentation, Apr 28, 2020
Slide 1: Eurofins Q1 2020 Management Update
Eurofins Q1 2020 Management Update Q1 2020 results & outlook Eurofins broad range of solutions to support the fight against the COVID-19 pandemic www.eurofins.com
Slide 2: Disclaimer
Disclaimer The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain
Slide 3: Q1 2020 Highlights
Q1 2020 Highlights 1. We mobilised all scientific resources to develop solutions to fight COVID- 19 - Eurofins is one of the few companies in the world that can contribute on so many levels ! 2. The vast majority of our activities are essential and continue to operate 3. Very early on we set up a va
Slide 4: Strong Q1 organic growth despite COVID-19 impact demonstrating resilience of underlying markets
Strong Q1 organic growth despite COVID-19 impact demonstrating resilience of underlying markets • Q1 2020 revenues increased 7% year-on-year to EUR 1,142m • 4.1% organic growth (4.6% excluding Boston Heart Diagnostics & two laboratories closed due to a fire), showing the resilience of Eurofins under
Slide 5: Decisive financial measures to protect cash while focusing more resources on COVID-19 testing & research
Decisive financial measures to protect cash while focusing more resources on COVID-19 testing & research • M&A and capex put on hold • Reduction of personnel costs • Hiring freeze & furloughs whenever needed • Freeze of compensation for its key employees and leaders (ca. 1,600 FTE) • Deferment of 20
Slide 6: Outlook: increase of COVID-19 testing & research services may compensate lockdown impact
Outlook: increase of COVID-19 testing & research services may compensate lockdown impact • Eurofins is positioned in resilient markets, with a large and diversified network of laboratories active in essential sectors such as Food, Water, BioPharma, Clinical and Genomics testing • Lockdown measures i
Slide 7: Eurofins broad range of solutions to support the fight against the COVID-19 pandemic
Eurofins broad range of solutions to support the fight against the COVID-19 pandemic 7
Slide 8: Eurofins priority is to mobilise all available scientific talent & resources to fight the COVID-19 pandemic
Eurofins priority is to mobilise all available scientific talent & resources to fight the COVID-19 pandemic • Our mission at Eurofins is “Testing for Life” • Few companies have so many scientific and technological possibilities to develop new solutions and services to combat the COVID-19 pandemic •
Slide 9: Highlight of main initiatives to date to help fight the COVID-19 pandemic
Highlight of main initiatives to date to help fight the COVID-19 pandemic • Real time Polymerase Chain Reaction (RT-PCR) tests for SARS-CoV-2 offered across 23 laboratories in 9 countries, ramping up to reach 100,000 tests per day from mid-May 2020 • Serology-based antibody testing offered across 13
Slide 10: Real-time PCR clinical testing for qualitative detection of SARS-CoV-2
Real-time PCR clinical testing for qualitative detection of SARS-CoV-2 • Launched early March in both Germany and the USA • Validated by many national health authorities including the FDA in the USA and the National Reference Centre in France Diatherix TEM-PCR • Also offered in the USA as part of Di
Slide 11: Leveraging external & internal capabilities to ramp up capacity of RT-PCR
Leveraging external & internal capabilities to ramp up capacity of RT-PCR • Amid tightening supply chain issues, Eurofins can rely on its 6 Genomics oligonucleotides production sites in the USA, Europe, India and Japan to produce probes, primers and positive controls, key components for RT- PCR test
Slide 12: Offering serology-based tests for antibody detection
Offering serology-based tests for antibody detection • Launched early April • Complementing PCR swab testing to help estimate the timing of infection, support epidemiology & vaccines development develop knowledge that may provide information about statistically reduced contagion risks • Now avai
Slide 13: Offering high specificity testing kits for serology-based IgA, IgG and IgM antibody detection
Offering high specificity testing kits for serology- based IgA, IgG and IgM antibody detection • Launched on 9 April 2020 • Range of testing kits for serology-based antibody detection of patients that have been exposed to COVID-19 • Produced by the Group’s 4 factories and partners • Available for go
Slide 14: Ramping up COVID-19 testing capacity example
Ramping up COVID-19 testing capacity example • Eurofins is ramping up production of its ELISA high throughput testing machines 14
Slide 15: Solutions to support the research for therapeutics against COVID-19
Solutions to support the research for therapeutics against COVID-19 • Eurofins unique expertise and network of laboratories is supporting numerous private and public actors in their mission to accelerate COVID-19 drug and vaccine development • Eurofins 35 BioPharma testing laboratories throughout th
Slide 16: Providing the right tools to facilitate genomics research against COVID-19
Providing the right tools to facilitate genomics research against COVID-19 • Detailed knowledge of SARS-CoV-2 and its characteristics is instrumental in order to identify fast and viable solutions to COVID-19 pandemic • Eurofins Genomics supports scientists from all areas in their essential work L
Slide 17: Solutions for the detection of SARS-CoV-2 on environmental surfaces and PPE
Solutions for the detection of SARS-CoV-2 on environmental surfaces and PPE • Launched in March for detecting the presence of SARS-CoV-2 virus on environmental surfaces, being rolled out globally to help for broad screening and monitoring of sanitation measures • Global testing, inspection and regul
Slide 18: Helping employers return to normal operating conditions
Helping employers return to normal operating conditions Eurofins is developing programs helping employees return to work safely: • Employer & workplace safety programmes • Employees testing • Environment testing • Eurofins is a leader in bacteriology sampling and testing for retail and industry in m
Slide 19: Proposing in-house mobile blood draw and remote sample collection
Proposing in-house mobile blood draw and remote sample collection • Eurofins Transplant Genomics and Viracor partnering with various mobile sample collection groups, to enable patients for kidney transplants to have samples collected remotely for analysis without requiring them to visit transplant c
Slide 20: Partnering with health authorities in many countries to help combat COVID-19
Partnering with health authorities in many countries to help combat COVID-19 • Following requests from government health authorities, Eurofins teams are working to massively increase capacity on its wide range of testing and kits offering… • …across most continents thanks to its unique global networ
Slide 21: Eurofins "Testing for Life"
Eurofins “Testing for Life” • Eurofins mission is « Testing for Life », this has never be more true than today, as we are actively engaged in the fight against the COVID-19 pandemic • Our scientists & entrepreneurs, gathered in a unique network of laboratories are offering a wide range of services d
Slide 22: Q&A
ova a eurofins Q&A